Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03779295
Other study ID # 1803028429
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date November 1, 2018
Est. completion date June 5, 2019

Study information

Verified date February 2022
Source West Virginia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Perioral dermatitis is an inflammation of the skin around the mouth. The cause of perioral dermatitis is unknown. Current treatment methods include oral antibiotics and topical calcenurin inhibitors, both of which produce side effects and have been relatively ineffective in the treatment of perioral dermatitis. The investigators hope to assess the efficacy of laser therapy in treatment of perioral dermatitis by using laser therapy on one half of the patients face and having patients apply topical medication (clindamycin) to their face for 8 weeks. The side of their face that receives laser therapy will be randomized. The investigators will assess the efficacy of laser therapy by counting the number of lesions that patients have before and after laser therapy, comparing photos of patient's perioral dermatitis before and after treatment, and having patient's rate their satisfaction of the treatment.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 5, 2019
Est. primary completion date June 5, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - age 18 years or older - perioral dermatitis for greater than 1 month - willing to return for follow-up visits 2 weeks, 4 weeks and 8 weeks following treatment. Exclusion Criteria: - skin type V or VI (due to risk of hyperpigmentation) - pregnant - breastfeeding - unable to understand English - mentally impaired - incarcerated

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Pulse laser dye therapy (Device name: Candela Family of Pulsed Dye Laser Systems. 501k Number: K050673.)
The face will be split and randomized, one half will receive pulsed laser dye therapy.
Drug:
Clindamycin
The entire face (both halves) will receive clindamycin.

Locations

Country Name City State
United States West Virginia University University Town Centre Dermatology Clinic Morgantown West Virginia

Sponsors (1)

Lead Sponsor Collaborator
West Virginia University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in number of lesions on side of the subject's face receiving laser therapy counting number of lesions on each side of the face initial study visit
Primary Change in number of lesions on side of the subject's face receiving laser therapy counting number of lesions on each side of the face 4 weeks
Primary Change in number of lesions on side of the subject's face receiving laser therapy counting number of lesions on each side of the face 8 weeks
Primary Change in number of lesions on side of the subject's face receiving clindamycin alone (NO laser therapy) counting number of lesions on each side of the face initial study visit
Primary Change in number of lesions on side of the subject's face receiving clindamycin alone (NO laser therapy) counting number of lesions on each side of the face 4 weeks
Primary Change in number of lesions on side of the subject's face receiving clindamycin alone (NO laser therapy) counting number of lesions on each side of the face 8 weeks
Secondary Patient opinion of side that improved more Patients will grade satisfaction of treatment by answering "Which side of their face improved more from treatment?" with the option of responding "the right side/the left side/they are the same." 4 weeks
Secondary Patient opinion of side that improved more Patients will grade satisfaction of treatment by answering "Which side of their face improved more from treatment?" with the option of responding "the right side/the left side/they are the same." 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT00232115 - Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis Phase 3
Completed NCT00403949 - A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis Phase 2
Completed NCT06461299 - Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis Phase 4